KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Bristol Myers Squibb (BMY) over the last 5 years, with Q4 2025 value amounting to -$2.4 billion.

  • Bristol Myers Squibb's Change in Accured Expenses fell 49209.88% to -$2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$441.0 million, marking a year-over-year decrease of 12971.7%. This contributed to the annual value of -$441.0 million for FY2025, which is 12971.7% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Change in Accured Expenses stood at -$2.4 billion for Q4 2025, which was down 49209.88% from $1.7 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Change in Accured Expenses ranged from a high of $1.8 billion in Q3 2024 and a low of -$2.4 billion during Q4 2025
  • Its 5-year average for Change in Accured Expenses is $161.8 million, with a median of $88.0 million in 2021.
  • Over the last 5 years, Bristol Myers Squibb's Change in Accured Expenses had its largest YoY gain of 14186.05% in 2022, and its largest YoY loss of 67692.31% in 2022.
  • Bristol Myers Squibb's Change in Accured Expenses (Quarter) stood at -$39.0 million in 2021, then plummeted by 676.92% to -$303.0 million in 2022, then skyrocketed by 30.36% to -$211.0 million in 2023, then plummeted by 91.94% to -$405.0 million in 2024, then tumbled by 492.1% to -$2.4 billion in 2025.
  • Its Change in Accured Expenses was -$2.4 billion in Q4 2025, compared to $1.7 billion in Q3 2025 and $881.0 million in Q2 2025.